Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys

Pharmaceutical Research

Volumn 14, Issue 3, 1997, Pages 329-336

  Feng, Meihua Rose ^a   Corbin, Ann E ^a   Wang, Yanfeng ^a   Christoffersen, Curt L ^a   Wiley, James N ^a   Strenkoski, C A ^a   Tucker, Evelyn V ^a   Ninteman, Francis W ^a   Meltzer, Leonard T ^a   Heffner, Thomas G ^a   Wright, D Scott ^a  

^a PFIZER INC   (United States)

Author keywords

Active metabolite; Antipsychotic; Monkey; Pharmacodynamics; Pharmacokinetics; Rat

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; DRUG METABOLITE; NEUROLEPTIC AGENT; PD 147693; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; ELECTROPHYSIOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SQUIRREL MONKEY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; DOPAMINE; MALE; MOTOR ACTIVITY; NEURAL INHIBITION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SAIMIRI;

EID: 8244240422     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012050121937     Document Type: Article

References (19)

1. T. Pugsley, D. Davis, C. Akunne, L. Cooke, S. Whetzel, R. Mackenzie, Y. Shih, D. Van Leeuwen, L. Demattos, B. Caprathe, J. Wright, J. Jean, L. Wise, and T. Heffner. J. Pharmacol. Exp. Ther. 274:898-911 (1995).
2. L. Meltzer, C. Christoffersen, A. Corbin, F. Ninteman, K. Serpa, J. N. Wiley, L. Wise, and T. Heffner. J. Pharmacol. Exp. Ther. 274:912-920 (1995).
3. M. Rose Feng, C. Strenkoski, T. Parker, and D. S. Wright. Pharm Res. 10:S-320 (1993).
4. M. Rose Feng, S. Bezek, A. Gandhi, C. Strenkoski, T. Woolf, and D. S. Wright. Pharm Res. 10:S-347 (1994).
5. J. Wright, D. Downing, M. Rose Feng, R. Hayes, T. Heffner, R. Mackenzie, L. Meltzer, T. Pugsley, and L. Wise. J. Med. Chem. 38:5007-5014, (1995).
6. T. Heffner, D. Downs, L. Meltzer, J. Wiley, and A. Williams. J. Pharmacol. Exp. Ther. 251:105-112 (1989).
7. M. Rose Feng, P. Siersma, C. Strenkoski, and D. S. Wright. J. Chromatogr. B. 665:193-199 (1995).
8. L. Sheiner, D. Stanski, S. Vozeh, R. Miller, and J. Ham. Clin. Pharmacol Ther 3:358-371 (1979).
9. D. Verotta and L. Sheiner. J Pharmacokin Biopharm 23(1):1-4 (1995).
10. M. Rose Feng, W. Mcnally, and L. Meltzer, unpublished data.
11. C. Walker. Drug metab Rev. 2:295-323, (1978).
12. M. Sinz, B. Michniewicz, and T. Woolf. Metabolic and species comparison of the antipsychotic agent CI-1007 using microsomes, hepatocyte, and purified enzymes. Poster for 4th International ISSX, Seattle, WA, 1995.
13. Wagner J (1993) Pharmacokinetics for the pharmaceutical scientist, Technomic, Lancaster - Basel.
14. J. Javaid. J. Clin. Pharmacol. 34:286-295 (1994).
15. A. Jørgensen. In J. W. Bridges and L. F. Chasseaud (eds.), Progress in Drug Metabolism. Taylor & Francis Ltd, 1986, Vol. 9 p 111-173.
16. W. Meuldermans, J. Hendrick, G. Mannen, K. Lavrijsen, C. Janssen, J. Bracke, L. Jeune, W. Lauwers, and J. Heykans. Drug Met. Dispos. 1:129-138 (1994).
17. O. Ogren, J. Laudstrom, and B. Nilsson. J. Neural Transm. 94:199-216 (1993).
18. Stephen R. Marder, John M. Davis, Philip G. Janicak. Clinical use of neuroleptic plasma levels. American Psychiatric Press, Inc. Washington DC, 1993.
19. P. Snoeck, A. Peer, M. Horton, G. Mannens, R. Woestenborghs, R., Meibach, J. Heykants. Psychopharmacology 122:223-229 (1995).